Needham Reiterates Buy on Cytokinetics, Maintains $108 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Cytokinetics (NASDAQ:CYTK) and maintained a price target of $108.
February 28, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reaffirmed a Buy rating on Cytokinetics, with a price target of $108, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst like Serge Belanger suggests a strong bullish sentiment towards Cytokinetics. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100